Company Description
ZIVO Bioscience, Inc., a research and development company, engages in licensing and selling natural bioactive ingredients derived from its proprietary algae cultures to animal, human, and dietary supplement and medical food manufacturers.
The company operates in the biotech and agtech sectors, with an intellectual property portfolio comprising proprietary algal and bacterial strains, biologically active molecules and complexes, production techniques, cultivation techniques, and patented or patent-pending inventions for applications in human and animal health.
Its products indications include poultry gut health, bovine mastitis, canine joint health, human immune modification, algal biomass for human consumption, and biomass for supporting skin health / anti-aging.
The company was formerly known as Health Enhancement Products, Inc. and changed its name to ZIVO Bioscience, Inc. in October 2014.
ZIVO Bioscience, Inc. is headquartered in Bloomfield Hills, Michigan.
| Country | United States |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 8 |
| CEO | John B. Payne |
Contact Details
Address: 21 E. Long Lake Road, Suite 100 Bloomfield Hills, Michigan 48304 United States | |
| Phone | (248) 452 9866 |
| Website | zivobioscience.com |
Stock Details
| Ticker Symbol | ZIVO |
| Exchange | OTCMKTS |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001101026 |
| CUSIP Number | 98978N200 |
| ISIN Number | SE0015961909 |
| Employer ID | 87-0699977 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| John B. Payne | President, Chief Executive Officer and Chairman of the Board |
| Keith R. Marchiando | Chief Financial Officer, Treasurer and Secretary |
| Dr. Harlan L. Miller III | Vice President of Technology and Global Supply |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 9, 2024 | SC 13D/A | [Amend] General statement of acquisition of beneficial ownership |
| Mar 15, 2024 | 10-K | Annual Report |
| Mar 14, 2024 | SCHEDULE 13D/A | Filing |
| Feb 15, 2024 | 8-K | Current Report |
| Feb 15, 2024 | 25-NSE | Filing |
| Jan 22, 2024 | SC 13D | General statement of acquisition of beneficial ownership |
| Jan 17, 2024 | 8-K | Current Report |
| Jan 5, 2024 | 8-K | Current Report |
| Jan 3, 2024 | 8-K | Current Report |
| Dec 11, 2023 | 8-K | Current Report |